Researchers from Northwestern University and Yale University have presented new preclinical data for KL-50, a small molecule under investigation for the treatment of glioblastoma. KL-50 was designed to fluoro-ethylate DNA bases, resulting in DNA inter-strand cross-links and subsequent DNA damage that triggers DNA mismatch repair (MMR)-independent apoptosis.
Bladder cancer is a challenging disease that poses significant risks to patients, often leading to a grim prognosis. Recent research has brought attention to chaperonin-containing tailless complex polypeptide 1 subunit 3 (CCT3), identified as an oncogene in multiple tumor types. However, its specific role in bladder cancer remains largely unexplored.
Benobio Co. Ltd. has discovered new benzothiophene derivatives acting as bromodomain-containing protein 2 (BD1 domain) (Brd2 BD1) inhibitors reported to be useful for the treatment of cancer.
Elgen Therapeutics Inc. has patented new 4-chromanone derivative proteolysis targeting chimera (PROTAC) compounds comprising a von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled with a WD repeat-containing protein 5 (WDR5; BIG3)-targeting moiety through a linker.
Work at Tango Therapeutics Inc. has led to the identification of new ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Eterna Therapeutics Inc. has announced plans to evaluate the ability of ERNA-101 to induce and modulate antitumor immunity in ovarian cancer and breast cancer models through a sponsored research agreement with The University of Texas MD Anderson Cancer Center.
RSS
